Project Summary
Liver cancer remains one of the most lethal cancers worldwide, second only to pancreatic ductal
adenocarcinoma (PDAC), with hepatocellular carcinoma (HCC) making up at least 85% of liver cancer cases.
The most effective treatment options for HCC are for early- to intermediate-stage HCC. Unfortunately, due to the
absence of signs and symptoms in the early stages, most HCC patients are not diagnosed until advanced-stage
of disease, and therefore can only be treated with systemic therapies. First-line therapy for advanced HCC was
recently updated to a combination treatment of atezolizumab plus bevacizumab, and while this update is
encouraging, progression-free survival currently remains around 7 months. Thus, more effective strategies to
treat advanced HCC are still desperately needed. Our lab recently identified an antisense oligonucleotide (ASO)
that targets glucose metabolism through alternative splicing of pyruvate kinase (PKM) pre-mRNA, which could
be used as a therapy to treat HCC. PKM pre-mRNA undergoes mutually exclusive alternative splicing that results
in expression of either the PKM1 or PKM2 isoform. PKM2 is well known to be preferentially upregulated in HCC.
Its low enzymatic activity can create a bottleneck at the end of glycolysis that potentially promotes tumor growth
by shunting upstream glycolytic intermediates into various biosynthesis pathways. Given that PKM1 has higher
enzymatic activity, our ASO-based PKM splice-switching (APSS) therapy is designed to redirect alternative
splicing from PKM2 to PKM1, thereby relieving the PKM2-induced bottleneck, and reducing the accumulation of
glycolytic intermediates. Currently, our therapy has achieved reduced tumor growth in two pre-clinical models of
HCC. Despite these promising results, we have yet to establish a precise metabolic explanation by which APSS
therapy results in reduced HCC growth, as well as to evaluate its efficacy in combination with current HCC
therapies. My hypothesis is that our APSS therapy reduces serine synthesis in HCC and promotes dependence
on extracellular serine to sustain production of purine nucleotides. Additionally, I hypothesize that combination
treatment of APSS therapy with sorafenib will re-sensitize sorafenib-resistant HCC tumors. I plan to utilize in vivo
stable isotope tracing with LC-MS in HCC xenografts in order to obtain a comprehensive profile of HCC
metabolism in response to APSS therapy. Additionally, I will establish sorafenib-resistant HCC xenografts in
order to identify potential synergy between our APSS therapy and sorafenib. The significance of the proposed
research is that it will: (i) improve our understanding of PKM alternative splicing in tumorigenesis; (ii) help to
identify synergistic therapies that reinforce the effects of our APSS therapy; and (iii) provide further justification
for the eventual testing of our APSS therapy in clinical trials for advanced HCC.